Correction: Corrigendum: Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China

Citations Over TimeTop 10% of 2016 papers

Abstract

Hepatitis B virus (HBV) infection is a critical global health issue and moderately epidemic in Western China, but HBV molecular epidemiology characteristics are still limited. We conducted this study to investigate HBV genotypes and antiviral resistant mutations in this multi-ethnic area. A total of 1316 HBV patients were recruited from four ethnic groups from 2011 to 2013. Genotypes and resistant mutations were determined by Sanger sequencing. Four genotypes (B, C, D and C/D) were identified. Genotype B and C were common in Han population, while genotype D was predominant in Uygurs. Genotype C was the major genotype in both Tibetans and Yis, and recombinant C/D was found in Tibetans only. Lamivudine resistance was common in all populations, especially in Hans with prevalence of 42.8%. Entecavir resistance was barely observed regardless of ethnicity. Genotype C isolates had higher rates of rtA181T/V than genotype B (13.5% vs. 5.1%, P < 0.001), in accordance with higher prevalence of resistance to adefovir (20.0% vs. 9.5%, P < 0.001). While incidence of resistant mutations to other drugs and clinical factors showed no difference among different genotypes. HBV genotypes and resistance-conferring mutations had different geographic and demographic distributions in Western China, which provided molecular epidemiology data for clinical management.

Related Papers

• → Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir–lamivudine combination therapy(2005)19 cited
• → Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after lamivudine retreatment(2008)7 cited
• → “De novo” combination with adefovir and lamivudine is more effective than adefovir “add on” and as effective as lamivudine monotherapy in antiviral treatment of chronic HBV infection(2008)
• Observation upon curative effect of lamivudine and adefovir combination therapy on patients with chronic hepatitis B(2011)
• Short-term overlap lamivudine treatment with adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B(2008)